medigraphic.com
ISSN 0035-0052 (Print)

2009, Number 3

<< Back Next >>

Rev Mex Pediatr 2009; 76 (3)

Sildenafil treatment in a child with pulmonary hypertension: The case of a toddler

González FAE, Aguilar AM, Rodríguez MR

Language: Spanish
References: 37
Page: 124-127
PDF size: 176.41 Kb.


ABSTRACT

The purpose of this report is to describe the clinical experience and the following related treatment of the response to the girl to the for heart pulmonary hypertension (HPT). She was born with congenital heart diseases (interauricular communication and arterious conduit persistence) and a Bochdalek’s diaphragmatic hernia. Two days after she born had a surgery for the correction of hernia and when she had six month age had other surgery in order to correct the heart malformations. At 22 months age diagnosis of heart pulmonary hypertension (HPT) was done and sildenafil treatment was stared at 2 mg/kg/dose every six hours with a good response. A year after with this treatment she had a progressive clinical respond and there was an echocardiographic improvement. At the three years of age she is asymptomatic.


REFERENCES

  1. Rashid A, Ivy D. Severe pediatric pulmonary hypertension: New Managements Strategies. Arch Dis Child 2005; 90: 92-98.

  2. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Reese H et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe

  3. persistent pulmonary hypertension of the newborn (PPHN). Pediatric Research 1996; 39(4) Supplement 2: 222.

  4. Rabinovitch M. Pathophysiology of pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescents. Seventh Edition. Lippincott, Williams & Wilkins, 2008: 1322.

  5. Doyle RL. Early diagnosis and treatment of pulmonary arterial hypertension. Medscape Pulmonary Medicine 2005; 9(1).

  6. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-5.

  7. Ivy DD, Griebel JL, Kinsella JP, Abman SH. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. J Pediatr 1998; 133(3): 453-6.

  8. Hill N. Therapeutic options for the treatment of pulmonary hypertension. Medscape Pulmonary Medicine 2005: 9(2).

  9. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-70.

  10. Khun K, Wickersham N, Robbins I, Byme D. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lungs Res 2004; 30(2): 135-45.

  11. Fernández N, Rodríguez A, Jerez J, Parrondo SM, Martínez L. Sildenafil oral como tratamiento de un neonato con hipertensión pulmonar persistente. Ann Pediatr 2004; 61(6): 567-8.

  12. Karatza AA, Busch A, Magee AG. Reversal of shunting in pulmonary hypertension after treatment with oral sildenafil. Cardiol Young 2002; 12(6): 561-2.

  13. Lepore JL, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM et al. Effect of sildenafil on the acute pulmonary vasodilatator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90(6): 677-80.

  14. Karatza AA, Busch A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100(2): 267-73.

  15. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81(9): 1157-61.

  16. Gohfrani HA, Wiedermann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial. Lancet 2002; 360(9337): 895-900.

  17. Rosenzwein EB, Barst RI. Clinical managements of patients with pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescent. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1355-68.

  18. Galie N, Ghofrani H, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20): 2148-57.

  19. Michelakis E, Tymchack W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403.

  20. Rashid A, Ivy D. Severe pediatric pulmonary hypertension: New Managements Strategies. Arch Dis Child 2005; 90: 92-98.

  21. Kinsella JP, Truog WE, Walsh WF, Goldberg RN, Bancalari E, Reese H et al. Randomized, multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe persistent pulmonary hypertension of the newborn (PPHN). Pediatric Research 1996; 39(4) Supplement 2: 222.

  22. Rabinovitch M. Pathophysiology of pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescents. Seventh Edition. Lippincott, Williams & Wilkins, 2008: 1322.

  23. Doyle RL. Early diagnosis and treatment of pulmonary arterial hypertension. Medscape Pulmonary Medicine 2005; 9(1).

  24. Yung D, Widlitz AC, Rosenzweig EB, Kerstein D, Maislin G, Barst RJ. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-5.

  25. Ivy DD, Griebel JL, Kinsella JP, Abman SH. Acute hemodynamic effects of pulsed delivery of low flow nasal nitric oxide in children with pulmonary hypertension. J Pediatr 1998; 133(3): 453-6.

  26. Hill N. Therapeutic options for the treatment of pulmonary hypertension. Medscape Pulmonary Medicine 2005: 9(2).

  27. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-70.

  28. Khun K, Wickersham N, Robbins I, Byme D. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lungs Res 2004; 30(2): 135-45.

  29. Fernández N, Rodríguez A, Jerez J, Parrondo SM, Martínez L. Sildenafil oral como tratamiento de un neonato con hipertensión pulmonar persistente. Ann Pediatr 2004; 61(6): 567-8.

  30. Karatza AA, Busch A, Magee AG. Reversal of shunting in pulmonary hypertension after treatment with oral sildenafil. Cardiol Young 2002; 12(6): 561-2.

  31. Lepore JL, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM et al. Effect of sildenafil on the acute pulmonary vasodilatator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90(6): 677-80.

  32. Karatza AA, Busch A, Magee AG. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 2005; 100(2): 267-73.

  33. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998; 81(9): 1157-61.

  34. Gohfrani HA, Wiedermann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial. Lancet 2002; 360(9337): 895-900.

  35. Rosenzwein EB, Barst RI. Clinical managements of patients with pulmonary hypertension. In: Moss and Adams. Heart disease in infants, children and adolescent. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2008: 1355-68.

  36. Galie N, Ghofrani H, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353(20): 2148-57.

  37. Michelakis E, Tymchack W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 2002; 105: 2398-403.




2020     |     www.medigraphic.com